Additionally, they attenuate mammalian target of rapamycin (mTOR) activity through the inhibition of AKT-mediated prolin-rich akt substrate (PRAS40) phosphorylation, indicating that GLP-1R agonists (GLP-1RAs) help to control inflammation and immune responses in hCASMCs, improve vascular health, and may positively impact the treatment of atherosclerosis by modulating the AKT and mTOR signaling pathways (Gallego-Colon et al., 2018; Li BY. Here, GLP1R is linked to atherosclerosis.